References
1. R.O. Williams, A.B. Watts, and D.A. Miller, "Preface" in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), p. v–viii.
2. K.P. O'Donnell and R.O. Williams, "Optimizing the Formulation of Poorly Water- Soluble Drugs," in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), pp. 27–28.
3. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage
Forms Based on a Biopharmaceutics Classification (Rockville, MD, Aug. 2000).
4. A.H. Jens-Uwe and R. H. Mueller, Int. J. Nanomedicine
3 (3), 295–310 (2008).
5. H. Chen et al., Drug. Discov. Today
16 (7–8), 354–360 (2011).
6. Alkermes, "NanoCrystal Technology" company information,
http://www.alkermes.com/Contract-Services/Technologies/Bioavailability-Enhancement, accessed Feb. 13, 2012.
7. SkyePharma, "2011 Half-Year Results" (London, Aug. 18, 2011).
8. SkyePharma, "Insoluble Drug Delivery Platform" company information,
http://www.skyepharma.com/Technology/Oral_Technology/Particle_Engineering_Technologies/Insoluble_Drug_Delivery_Platform/Default.aspx?id=80, accessed Feb. 13, 2012.
9. Aptalis Pharmaceutical Technologies, "Biorise Technology" company information,
http://www.aptalispharmaceuticaltechnologies.com/tech_biorise.html, accessed Feb. 13, 2012.
10. B. Trout et al., J. Pharm. Sci. 101 (3), 1178–1188 (2012).
11. P. Van Arnum, Pharm. Technol. 32 (7), 96–98 (2007).
12. P. Van Arnum, Pharm. Technol.
35 (7), 46 (2011).
13. J.Q. Thomassen and P. Holm, presentation at the Nanomedicine and Drug Delivery Symposium (Toronto, Nov. 2008).
|
